MOUD Buprenorphine Sublocade denied as not medically necessary by Express Scripts?

Sublocade requires 7+ days sublingual buprenorphine stabilization before LA injectable approved.

Patient-specific justification: prior buprenorphine non-adherence, diversion concerns, work/travel adherence challenges, prior overdose, pregnancy. ASAM NPG OUD 2020. Cite HOFER pivotal (Haight 2019, Lancet). MHPAEA 2024 Final Rule NQTL — demand comparative analysis.

## Why Express Scripts Denies Sublocade on Medical Necessity — and How to Appeal

Express Scripts (ESI) and the health plans it administers apply medical-necessity criteria to Sublocade (buprenorphine extended-release subcutaneous injection) before approving a prior authorization. A medical-necessity denial typically means the plan's reviewer concluded that the submitted documentation did not demonstrate that Sublocade — rather than a less expensive or more "standard" formulation — was required for this specific patient.

Common reasons for these denials include: the prescriber submitted minimal documentation; the plan requires evidence of a sublingual buprenorphine trial first; or the plan's criteria require documented adherence challenges, diversion risk, or other patient-specific factors that were not addressed in the initial submission. These gaps are fixable on appeal.

## Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): File within 180 days of the denial. ESI-administered plans must respond within 30 days (pre-service) or 60 days (post-service).
• Expedited internal appeal: If the standard timeline would seriously jeopardize the patient's health or treatment continuity, request expedited review — response required within 72 hours.
• External independent review (ACA §2719): After exhausting internal appeals, you have approximately four months from the original denial to request external review by an independent organization. Medical-necessity reversals at external review are common when documentation is thorough.
• MHPAEA parity: If the medical-necessity standards for Sublocade are more stringent than for comparable non-behavioral-health medications, a parity challenge applies.

## The Appeal Process

1. Request the plan's written medical-necessity criteria for Sublocade — ESI must provide this. 2. Compare the criteria to the documentation submitted with the original PA request, and identify every gap. 3. Obtain supplemental documentation addressing each gap. 4. File a written internal appeal with a criteria-mapped letter from the prescriber. 5. Request external review if the internal appeal is denied.

## Documentation to Gather

• Diagnosis confirmation: DSM-5 opioid use disorder diagnosis, severity specifier, date of diagnosis, and treating clinician credentials.
• Prior treatment history: Dates, formulations, and outcomes of prior MOUD trials (sublingual buprenorphine, naltrexone, methadone — whichever applies), including reasons any prior agent was discontinued or proved insufficient.
• Clinical rationale for injectable formulation: Prescriber documentation of patient-specific factors that make Sublocade medically appropriate — such as adherence history, risk factors for diversion or misuse of daily oral doses, patient preference supported by clinical judgment, or clinical instability on prior formulations.
• Severity and comorbidities: Chart documentation of overdose history, co-occurring psychiatric or medical conditions, and functional status.
• Prescriber medical-necessity letter: A detailed letter mapping each plan criterion to specific chart facts, and referencing the FDA-approved prescribing information and applicable ASAM/SAMHSA guidelines generically.

## Criteria-Mapping Structure

The single most effective appeal tool is a table that lists every criterion from ESI's published medical-necessity policy and answers each one with a specific chart fact:

| Plan Criterion (from ESI policy) | Supporting Documentation | |---|---| | Diagnosis of moderate-to-severe OUD | [Date, DSM-5 criteria, clinician] | | Prior MOUD trial or documented rationale for Sublocade | [Treatment history with dates and outcomes] | | Adherence or safety rationale for injectable | [Chart documentation of specific factors] | | Prescribing clinician certification/waiver | [Provider credential confirmation] | | Consistent with FDA-approved labeling | [Prescriber attestation] |